LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Announcement of the two-year follow-up results of the FIM clinical trial of IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 5 November 2021, the two-year follow-up results of the FIM clinical trial (the "**FIM Clinical Trial**" or the "**Clinical Trial**") of self-developed IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System ("**IBS® Coronary Scaffold**" or the "**Product**") was announced in the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2021 ("**TCT 2021**") by Professor Gao Runlin. The Clinical Trial is the world's first clinical trial of iron-based bioresorbable scaffold.

The results of the FIM Clinical Trial showed that the IBS® Coronary Scaffold had favorable preliminary mid-term efficacy and safety in the treatment of non-complex de novo coronary artery lesions. No deaths, myocardial infarctions or thrombosis cases were reported in the two-year follow-up, demonstrating the good safety of IBS® Coronary Scaffold. The efficacy results of the IBS® Coronary Scaffold are also comparable to other mainstream permanent stents. The success rate of the Clinical Trial is 100%, and almost all the scaffold struts had been degraded in two years, with no malapposition during the degradation process.

The confirmatory clinical trials in China of IBS® Coronary Scaffold were approved on 25 August 2021, and with the advancement of follow-up clinical trials, there will be more clinical evidences to further confirm the safety and effectiveness of the Product. Upon successful launch of the Product, the IBS® Coronary Scaffold is expected to be an unprecedented treatment for patients with coronary heart disease all over the world.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 9 November 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.